Skip to site content
U.S. Department of Health and Human Services
Division of Diabetes Treatment and Prevention (DDTP)

Part 3: MASLD: Medication Management and Monitoring

Quiz for CE Credit

This quiz consists of multiple choice questions with one correct answer.
Please select one answer for each question, then click the Submit Answers button at the end of the quiz.

 
1. Hyperglycemia from diabetes can cause lipotoxicity, which alters the way the liver processes and stores lipids, contributing to fat accumulation and inflammation.


 
2. The American Diabetes Association (ADA) 2025 Standards of Care recommends the use of a GLP-1 receptor agonist or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist with potential benefits in metabolic dysfunction-associated steatohepatitis (MASH) for glycemic management and as an adjunctive to healthy interventions for weight loss.


 
3. Combination therapy with pioglitazone plus a GLP-1 receptor agonist can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis because of the potential beneficial effects on MASH.


 
4. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) targets an individualized approach for treatment targeting the following:





 
5. Liver-directed medication therapy for advanced fibrosis includes the use of Resmetirom or Semaglutide.


 
6. The following are contraindications to prescribing pioglitazone for the treatment of MASLD:




 
7. The two primary liver-associated end points currently accepted by regulatory agencies for conditional approval of a new drug for the treatment of MASH include 1) MASH resolution without worsening of liver fibrosis and 2) the improvement in fibrosis by at least one stage without the worsening of MASH.


 
8. A patient with type 2 diabetes who has or is at risk for MASLD would benefit from which of the following:




 
9. Statin therapy is safe in adults with type 2 diabetes and compensated cirrhosis from MASLD and should be initiated or continued for cardiovascular risk reduction, as clinically indicated.